According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the phase I clinical trial of the SYH2092 injection developed by the group for weight management in adult overweight or obese patients has officially started at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.